# SLC4A10 impedes atherosclerosis by diminishing IFN-γ/GZMB levels of CD8+ T cells via the MAPK pathway

**Authors:** Bo Chen, Lei Zhu, Xueguang Lin, Kristine J. S. Kwan, Jie Wang, Yijie Lu, Jialong Li, Ying Deng, Shuai Jiang, Jingdong Tang, Bo Yu

PMC · DOI: 10.3389/fimmu.2025.1568999 · Frontiers in Immunology · 2025-05-29

## TL;DR

This study shows that SLC4A10 reduces atherosclerosis by lowering harmful CD8+ T cell activity through the MAPK pathway.

## Contribution

The novel finding is that SLC4A10+ CD8+ T cells reduce atherosclerosis via the MAPK pathway by decreasing IFN-γ/GZMB levels.

## Key findings

- SLC4A10+ CD8+ T cells are enriched in unstable atherosclerotic plaques and correlate with vascular smooth muscle cell apoptosis.
- SLC4A10 overexpression reduces granzyme B and IFN-γ levels in CD8+ T cells, mitigating plaque progression.
- MAPK pathway genes like MAPK2K6, ELK4, and MAP3K5 are differentially expressed in SLC4A10+ CD8+ T cells.

## Abstract

CD8+ T cell subpopulations participate in the formation of atherosclerotic plaques through activation or exhaustion. Yet, it is unclear which specific subset it critically involved. The SLC4A10+ CD8+ T cell possess atherogenic attributes and this study aimed to investigate the associated pathway involved in affecting plaque stability.

Carotid plaques were collected from patients that underwent carotid endarterectomy in our institute and categorized into stable or unstable plaques. The SLC4A10+ CD8+ T cell subset were investigated. For in vivo analysis, carotid artery tangem ligation was performed in 8-week-old, AAV-6 overexpressed mice fed with high-fat diet to acquire unstable carotid plaques. Isolated CD8+ T cells were cultivated and their immunopathological characteristics were examined in vitro.

SLC4A10+ CD8+ T cells were significantly enriched in unstable human carotid plaques and were correlated with the apoptosis of vascular smooth muscle cells (VSMCs). SLC4A10-overexpressed mice, serum IL-4, IL-17A, and IL-6 were increased, while the level of granzyme B (GZMB) decreased. The extent of atherosclerotic plaques was mitigated, the amount of collagen fibers were diminished, and the apoptosis of VSMCs were alleviated. Flow cytometry suggested that SLC4A10 decreased the levels of IFN-γ and GZMB in CD8+T cells. The CCK8 demonstrated that IFN-γ and GZMB lead to the decrease in MOVAS cell viability. KEGG analysis revealed that SLC4A10+ CD8+ T cells participated in the MAPK pathway, cytokine-cytokine receptor interaction, TNF signaling pathway, and cell adhesion molecule pathway. The differential expression of related genes MAPK2K6, ELK4, and MAP3K5 in the MAPK pathway were verified.

These data demonstrate that SLC4A10 mitigates cytotoxicity by decreasing the levels of IFN-γ/GZMB of SLC4A10+ CD8+ T cells via the MAPK pathway, which impedes plaque progression and aids stabilization.

## Linked entities

- **Genes:** SLC4A10 (solute carrier family 4 member 10) [NCBI Gene 57282], ELK4 (ETS transcription factor ELK4) [NCBI Gene 2005], MAP3K5 (mitogen-activated protein kinase kinase kinase 5) [NCBI Gene 4217]
- **Proteins:** IFNG (interferon gamma), GZMB (granzyme B), IL4 (interleukin 4), IL17A (interleukin 17A), IL6 (interleukin 6)
- **Diseases:** atherosclerosis (MONDO:0005311)

## Full-text entities

- **Genes:** Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Map3k5 (mitogen-activated protein kinase kinase kinase 5) [NCBI Gene 26408] {aka 7420452D20Rik, ASK, ASK1, MAPKKK5, Mekk5}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Slc4a10 (solute carrier family 4, sodium bicarbonate cotransporter-like, member 10) [NCBI Gene 94229] {aka NCBE, mKIAA4136}, Elk4 (ETS transcription factor ELK4) [NCBI Gene 13714] {aka 2310011G17Rik, A130026I01Rik, SAP-1, Sap1}, Il17a (interleukin 17A) [NCBI Gene 16171] {aka Ctla-8, Ctla8, IL-17, IL-17A, Il17}, Il4 (interleukin 4) [NCBI Gene 16189] {aka BSF-1, Il-4}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Gzmb (granzyme B) [NCBI Gene 14939] {aka CCP-1/C11, CCP1, Ctla-1, Ctla1, GZB}
- **Diseases:** Carotid plaques (MESH:D016893), cytotoxicity (MESH:D064420), atherogenic (MESH:D050197), atherosclerotic plaques (MESH:D058226)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** MOVAS — Mus musculus (Mouse), Transformed cell line (CVCL_0F08), CCK8 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_2873)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12159029/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12159029/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC12159029/full.md

---
Source: https://tomesphere.com/paper/PMC12159029